Shanghai Universal Biotech Co.,Ltd. (SHE:301166)
China · Delayed Price · Currency is CNY 33.45
-0.59 (-1.73%)
Feb 11, 2026, 4:00 PM EST
SHE:301166 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,066 | 1,118 | 1,226 | 1,195 | 1,110 | 849.08 |
| 1,066 | 1,118 | 1,226 | 1,195 | 1,110 | 849.08 | |
Revenue Growth (YoY) | -8.67% | -8.82% | 2.57% | 7.70% | 30.69% | 7.90% |
Cost of Revenue | 873.9 | 916.48 | 995.73 | 930.56 | 852.59 | 657.08 |
Gross Profit | 192.19 | 201.28 | 230.1 | 264.56 | 257.08 | 192 |
Selling, General & Admin | 175.65 | 167.86 | 173.8 | 134.14 | 109.06 | 91.22 |
Research & Development | 64.11 | 61.31 | 56.62 | 32.14 | 16.31 | 8.73 |
Other Operating Expenses | 2.47 | 3.88 | 2.15 | 1.25 | 3.38 | 2.98 |
Operating Expenses | 250.93 | 239.19 | 236.31 | 178.74 | 131.75 | 105.87 |
Operating Income | -58.73 | -37.91 | -6.21 | 85.82 | 125.33 | 86.12 |
Interest Expense | -1.04 | -1.04 | -2.06 | -1.29 | -0.11 | -0.39 |
Interest & Investment Income | 17.57 | 23.74 | 24.99 | 27.11 | 3.53 | 2.82 |
Currency Exchange Gain (Loss) | -2.11 | -2.11 | -3.24 | -2.83 | 0.22 | 2.1 |
Other Non Operating Income (Expenses) | 0.02 | -0.29 | -0.47 | -0.52 | -0.36 | -0.41 |
EBT Excluding Unusual Items | -44.3 | -17.61 | 13.01 | 108.29 | 128.61 | 90.25 |
Gain (Loss) on Sale of Investments | 11.07 | 13.91 | 15.24 | 14.5 | - | -0.22 |
Gain (Loss) on Sale of Assets | -1 | -1.24 | -0 | 0.01 | -0.24 | - |
Asset Writedown | -1.24 | -0 | -0 | - | - | - |
Other Unusual Items | 5.6 | 5.76 | 7.24 | 5.72 | 9.29 | 5.7 |
Pretax Income | -29.87 | 0.82 | 35.48 | 128.52 | 137.65 | 95.74 |
Income Tax Expense | -10.86 | -9.33 | -4.84 | 21.92 | 28.93 | 19.25 |
Net Income | -19.01 | 10.15 | 40.32 | 106.6 | 108.73 | 76.49 |
Net Income to Common | -19.01 | 10.15 | 40.32 | 106.6 | 108.73 | 76.49 |
Net Income Growth | - | -74.83% | -62.18% | -1.96% | 42.15% | 32.01% |
Shares Outstanding (Basic) | 85 | 85 | 86 | 87 | 65 | 65 |
Shares Outstanding (Diluted) | 85 | 85 | 86 | 87 | 65 | 65 |
Shares Change (YoY) | -1.16% | -1.41% | -1.02% | 32.32% | 1.05% | 4.04% |
EPS (Basic) | -0.22 | 0.12 | 0.47 | 1.23 | 1.66 | 1.18 |
EPS (Diluted) | -0.22 | 0.12 | 0.47 | 1.23 | 1.66 | 1.18 |
EPS Growth | - | -74.47% | -61.79% | -25.90% | 40.68% | 26.88% |
Free Cash Flow | -49.53 | 4.77 | -85.87 | -204.8 | 44.72 | 87.28 |
Free Cash Flow Per Share | -0.58 | 0.06 | -1.00 | -2.36 | 0.68 | 1.35 |
Dividend Per Share | 0.230 | 0.230 | 0.470 | 0.900 | 0.500 | - |
Dividend Growth | -51.06% | -51.06% | -47.78% | 80.00% | - | - |
Gross Margin | 18.03% | 18.01% | 18.77% | 22.14% | 23.17% | 22.61% |
Operating Margin | -5.51% | -3.39% | -0.51% | 7.18% | 11.29% | 10.14% |
Profit Margin | -1.78% | 0.91% | 3.29% | 8.92% | 9.80% | 9.01% |
Free Cash Flow Margin | -4.65% | 0.43% | -7.00% | -17.14% | 4.03% | 10.28% |
EBITDA | -42.71 | -24.21 | 4.39 | 92.32 | 130.52 | 92.34 |
EBITDA Margin | -4.01% | -2.17% | 0.36% | 7.72% | 11.76% | 10.88% |
D&A For EBITDA | 16.02 | 13.7 | 10.6 | 6.5 | 5.19 | 6.22 |
EBIT | -58.73 | -37.91 | -6.21 | 85.82 | 125.33 | 86.12 |
EBIT Margin | -5.51% | -3.39% | -0.51% | 7.18% | 11.29% | 10.14% |
Effective Tax Rate | - | - | - | 17.05% | 21.01% | 20.11% |
Revenue as Reported | 1,066 | 1,118 | 1,226 | 1,195 | 1,110 | 849.08 |
Advertising Expenses | - | 4.05 | 9.56 | 5.81 | 5.08 | 3.53 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.